Biomarker Articles & Analysis

We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to detect thermal (infrared) biomarkers of diabetic peripheral neuropathy on the feet of diabetic subjects who have not been diagnosed with DPN. By analyzing ...

By VisionQuest Biomedical Inc.

ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...

By ImCare Biotech, LLC

Dynacare Launches JOINTstat® Testing in Canada Augurex is pleased to announce the launch of JOINTstat (14-3-3?) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives with commitment and care. This arrangement will make JOINTstat testing accessible to more patients and physicians ...

By Augurex Life Sciences Corp.

BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its poster abstract has been accepted for presentation at the upcoming 70th Annual Conference of the American Society for Mass Spectrometry (ASMS) taking place on June 5 – 9, 2022 ...

By BioMark Diagnostics Inc.

BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. The financing round included a non-brokered private ...

By BioMark Diagnostics Inc.

Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing ...

By BioMark Diagnostics Inc.

EIC Accelerator is the biggest funding round supported by the European Commission, with a total budget of 637 million euros and more than 90 million euros to be distributed between the 11 Spanish start-ups selected, including Amadix. To be part of the EIC Accelerator is a big boost for the company and the commercialization of Amadix’ firs product, PREVECOL® (previously known as ...

By Amadix

During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...

By HORIBA Europe GmbH

BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...

By BioMark Diagnostics Inc.

Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug development company, announced on ...

By GI Innovation

Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug development company, announced on February ...

By GI Innovation

ISPRM 2022 is now over | International Society of Physical and Rehabilitation Medicine | Lisbon PT After 4 nice days and some smart presentations, ISPRM 2022 now ends with great memories. New device presentation: IVS4 for Lower Limbs as a complementary approach to balance exercise, strengthening and robotic rehabilitation for gait recovery Lecture: Comparison of EEG biomarkers in Mirror ...

By Dessintey | Parc Technologique Metrotech

VisionQuest founder and CEO Peter Soliz (PhD) presented the poster “Detecting diabetic peripheral neuropathy utilizing thermoregulation biomarkers of the plantar foot” at the American Diabetes Association’s 82nd Scientific Sessions last Sunday in New Orleans. “I was so glad to be able to meet with colleagues and make new connections in person after not traveling for over ...

By VisionQuest Biomedical Inc.

Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases. "Insilico is advancing its latest target identification ...

By Insilico Medicine

Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis. During this webinar you will learn how the new features of the fully-automated XelPleX system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ...

By HORIBA Europe GmbH

Vancouver, British Columbia – (September 8, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it’s abstract titled “Metabolomic Profiling for the Early Detection of Lung Cancer” has been ...

By BioMark Diagnostics Inc.

Regeneus has partnered with the Allogeneic STEM cell manufacturing Programme (ASTEM) to investigate the status of a novel genomic biomarker within their adipose donor banks. This work is being conducted at one of the partner institutes of the ASTEM Programme, the Genome Institute of Singapore, which is a leading Research Institute within the Agency for Science, Technology and Research ...

By Regeneus Ltd.

MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role ...

By CD Genomics

In a recent article, Prof Daniel Salerno, Prof Victor Kim and colleagues used Functional Respiratory Imaging to better understand the crucial link between DLCO and Pulmonary Vascular Abnormalities in COVID19. COVID-19 is a respiratory viral illness causing pneumonia and systemic disease. Abnormalities in pulmonary function tests infection have been described. The determinants of these ...

By Fluidda

USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex’s Portfolio in the Diagnosis of Rheumatoid Arthritis (RA) On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From Citrullinated 14-3-3 And Uses Thereof In The Diagnosis of Rheumatoid Arthritis.” Citrullinated 14-3-3η auto-antibodies are ...

By Augurex Life Sciences Corp.